Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

By sjmartinez • May 22, 2024

Bryce AH, Crawford ED, Agarwal N, Hussain MH, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr;2(4):e00032. doi: 10.1097/ju9.0000000000000138. Epub 2024 Apr 15. PMID: 38774467; PMCID: PMC11107999.

Tags: Hematology/Oncology, Publications, Veterans Administration

Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital

Chao E, Marshalek JP, Yashar D, Tomassetti S. Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital. SAGE[...]

Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence

Conforti F, Merlo F, Pala L, Canzian J, Tinterri B, De Pas T, Locatelli M, Dickerson JC, Cortes J, Slamon DJ, Gelber R, Bagnardi V.[...]

Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis

Leslie LA, Baird JH, Flinn IW, Tees M, Hoda D, Deol A, Young P, McClune B, Varadarajan I, Essell J, Fanning S, Simmons G, Clark[...]